DocStoX is a free AI-powered research platform for Indian equity markets, covering 6,800+ NSE & BSE stocks with prices, fundamentals, 326 financial ratios, shareholding, FII/DII flows, F&O, IPOs, a visual screener and AI stock scoring.

Yes. DocStoX has a free tier covering stock research, the screener, FII/DII data and educational guides, plus a free MCP API tier (50 tool calls/day) for AI assistants. A Pro plan adds higher limits and advanced features.

What data does DocStoX cover?

Every NSE & BSE listed stock (6,800+ instruments): EOD and intraday prices, income statement / balance sheet / cash flow, 326 ratios, quarterly shareholding, promoter pledge, mutual-fund holdings, FII/DII flows, F&O and option-chain data, analyst forecasts, IPOs, corporate actions and news.

Can AI assistants like ChatGPT or Claude use DocStoX data?

Yes. DocStoX runs a public Model Context Protocol (MCP) server at https://mcp.docstox.com/mcp with 39 tools, so Claude, ChatGPT, Cursor and other MCP clients can pull Indian market data directly. Setup and a free key are at https://docstox.com/mcp.

All news

Neutral impactCompany

Avience Biomedicals Limited — Certificate under SEBI (Depositories and Participants) Regulations, 2018

NSE 42 min ago·29 Jul 2026, 2:50 pm

AVIENCE NSE

Avience Biomedicals Limited has informed stock exchanges that it has received a certificate under SEBI Regulation 74(5). This certificate confirms that the company has successfully complied with all its obligations regarding the dematerialization of its securities. Essentially, it is a formal declaration that the company's shares are ready for electronic trading.

This development is a routine regulatory compliance measure. It ensures that the company's shares are fully eligible for trading on the stock market. For investors, this is a neutral update that confirms the company's adherence to market regulations, though it does not indicate any specific financial performance or operational news.

Investors should view this as a standard administrative update. It does not signal any immediate change in the company's business prospects. Moving forward, market participants should monitor the company's regular financial disclosures for any material updates that could impact the stock price.